Abstract
Summary This article discusses the strategies and trajectories deployed by the Forum for the Advancement of Immunization Research (FAIR) to rehabilitate Salk’s inactivated polio vaccine (IPV), at a time when Sabin’s oral polio vaccine (OPV) had come to dominate the global polio vaccine market. FAIR was an international coalition of scientists and institutions that undertook specific field studies to establish the conditions under which IPV could usefully be introduced in developing countries. Regardless of the evidence it gathered, FAIR failed to convince WHO to integrate IPV into the Expanded Programme on Immunization (EPI). This study of the life of IPV vaccine beyond its initial development and introduction, provides insights in the interplay of evidence and interests in the political decisions made around vaccination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
